Mov­ing on from a tri­al dis­as­ter, Juno re­ports pos­i­tive da­ta for JCAR017 -- and a death

Look­ing to dis­tance it­self from a tri­al dis­as­ter that claimed 5 lives last year, Juno Ther­a­peu­tics $JUNO to­day turned to a batch of pos­i­tive ear­ly-stage non-Hodgkin lym­phoma da­ta on its new lead CAR-T ther­a­py, JCAR017.

In­ves­ti­ga­tors for the biotech say that they have gath­ered da­ta that demon­strate its promise, out­lin­ing a com­bined over­all re­sponse rate of 86% and a com­plete re­sponse rate of 59% — 26 out of 44 pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.